All News
Pulmonary Arterial Hypertension in #AOSD
Rare but severe complication - life threatening
French study of 13 pts - network dataset. ALL FEMALES!
Age 32, mean f/u 34 mths, 5 pts (38.5%) DIED
@RheumNow #ACRBest abst#1100 https://t.co/5LIzHagesP
Bella Mehta bella_mehta ( View Tweet)
Towards better assessment and management of multimorbidity by Dr. Mrinalini Dey ( @DrMiniDey ) #ACR21
https://t.co/7DPGsVB6bG https://t.co/F57k44AWZ4
Links:
Dr. John Cush RheumNow ( View Tweet)
Knowledge Bowl at #ACR21
⭐️Approximately half of patients with IIM who develop pneumomediastinum have this subtype of dermatomyositis.
➡️Amyopathic (MDA5) dermatomyositis
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Knowledge Bowl at #ACR21
⭐️In a suspected PAN case, you order a peripheral smear to look for this potential etiology,
➡️Hairy cells
@RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
JAK-pot registry-based study. Following JAKi failure should you switch mode of action or go to second JAKi? Both seem equally effective in terms of drug retention. Didn't matter if switch for efficacy or adverse event. Abstr#1442 #ACR21 @RheumNow https://t.co/QEBB3flArC
Richard Conway RichardPAConway ( View Tweet)
#ACR21 Abs#1442: JAKpot - Cycle JAK or switch to bDMARD after JAK failure?
▶️No difference between cycle vs bDMARD group
▶️Non-signif trends: cycled JAK better for inefficacy to 1st JAK, bDMARD better for adverse effects
@Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/upfI6tDH1p
Links:
Eric Dein ericdeinmd ( View Tweet)
First JAKi failure: What's next? Wanna find out? It's here
https://t.co/o5CE1MBzUu
Abstr#1442 #ACR21 @RheumNow https://t.co/f0sdPn5mcZ
Aurelie Najm AurelieRheumo ( View Tweet)
Trauma associates with subsequent increased flares of SLE. Abstr#1446 #ACR21 @RheumNow https://t.co/QeNXOjHAjn
Richard Conway RichardPAConway ( View Tweet)
Tell me there's no collegiality on the #ACR21 virtual platform!
kudos to @ACRheum for making this thing run so smoothly, year-on-year
(and I'm telling you, the value's in the chat and the questions)
@RheumNow @Janetbirdope https://t.co/XJZArHIdnc
David Liew drdavidliew ( View Tweet)
Can you win the JAK pot twice? Equal effectiveness of JAK to JAK in #RheumatoidArthritis vs JAK to bDMARD. If d/c due to AE w JAK seemed to recur w 2nd JAK. Not RCT ?Channeling bias. But JAKi were worse off at baseline but did= switch v swap #ACR21 #ACRBest abst#1442 @RheumNow https://t.co/SRXMHdUBJF
Janet Pope Janetbirdope ( View Tweet)
Dr Jafarzadeh @Tuhina_Neogi on association NSAID use with TKR. At same level of pain, NSAID users appear to have more TKR. Is this same phenomenon we see with IA steroids (and tanezumab?)⬇️pain⬆️use⬆️damage? Abstr#1447 #ACR21 @RheumNow https://t.co/oY2ckmui0D
Richard Conway RichardPAConway ( View Tweet)
Long-term follow up of REDO study of ultra-low dose RTX (200mg vs 500mg vs 1000mg every 6 months) in RA. All doses appeared similarly effective, but also had similar adverse events. Potentially cost and time saving. Abstr#1443 #ACR21 @RheumNow https://t.co/0FRYPUOMpY
Richard Conway RichardPAConway ( View Tweet)
#ACR21 Ab#1443 by @NathandBroeder: Ultra-low dose RTX in RA?
⭐️RTX 200mg
▶️High retention in all groups- only 7 pts (6%) switched therapy. No diff in disease activity bw 200/500/1000mg
Great initial data, want more data on CD19/20, Ifns, etc.
@Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/X1jCcw3h0I
Links:
Eric Dein ericdeinmd ( View Tweet)
?Save $ and ⬇️bad #COVID19 outcomes by using ultra low dose #Rituximab in #RheumatoidArthritis retreatmet after responding to 1g. Not quite same benefit and sl earlier repeat dosing. @RheumNow #ACR21 #ACRBest abst#1443 Impt study https://t.co/SFZKpTYJXP
Janet Pope Janetbirdope ( View Tweet)
Way to go Texas!
#ACRknowledgebowl winners #GullsofGalveston when they answered the final jeopardy round: This monogenic dz can mimic Behcet’s syndrome and occurs due to mutation in TNFAIP3 @utmbhealth #ACR21 @rheumnow
...What is ...Haploinsufficiency A20? https://t.co/ExjKqtykVy
TheDaoIndex KDAO2011 ( View Tweet)
Dr Sherbini @james_gwinnutt @khyrich on baseline factors associated with nausea and alopecia with MTX. Alcohol use (modifiable!) and 👩 assoc with both. Disease activity with nausea. HAQ with alopecia. Abstr#1444 #ACR21 @RheumNow #ACRBest https://t.co/e0BG9omnEv
Richard Conway RichardPAConway ( View Tweet)
axSpA and Depression
71 axSpA patients surveyed
Abnormal HADs-D scores ▶️Significantly worse BASDAI and AQoL scores
Severe PHQ-9 scores ▶️worse BASDAI, BASFI and ASQoL
Abst# 1305 #ACR21 @RheumNow https://t.co/Sf2Rm6z7ln
swethaann23 swethaann23 ( View Tweet)
#ACR21 Ab#1444 @AhmadSherbini. Factors ass w/ nausea & alopecia in MTX
⭐️Nausea & alopecia: ♀️, 🥃, activity score are risk factors
▶️EtOH highlights importance of folic acid in these pts!
@Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/lxB2z2lXtu
Links:
Eric Dein ericdeinmd ( View Tweet)
Rheumatology Research Foundation Lecture: Learning lessons from @Google to harness #omics to better understand #RA
#ACR21 @RheumNow @RheumResearch https://t.co/NVAe2Rqo1O
Mrinalini Dey DrMiniDey ( View Tweet)
Love-hate relationship with #methotrexate. Side effects are common ex nausea/GI in 1/3 and alopecia in women. ?if you ask do you get more AES. Tough to treat especially SEs are early. ?Coach pt to help w persistence abst1444# @RheumNow #ACR21 https://t.co/NDQDVz8lk2
Janet Pope Janetbirdope ( View Tweet)